Charles Schwab Investment Management Inc. Boosts Holdings in Werewolf Therapeutics, Inc. $HOWL

Charles Schwab Investment Management Inc. boosted its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 33.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,712 shares of the company’s stock after acquiring an additional 23,852 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.21% of Werewolf Therapeutics worth $93,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in HOWL. Northern Trust Corp grew its position in shares of Werewolf Therapeutics by 7.3% during the fourth quarter. Northern Trust Corp now owns 244,390 shares of the company’s stock worth $362,000 after acquiring an additional 16,640 shares during the last quarter. Bridgeway Capital Management LLC lifted its position in shares of Werewolf Therapeutics by 24.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company’s stock worth $162,000 after purchasing an additional 21,500 shares in the last quarter. Deutsche Bank AG lifted its position in Werewolf Therapeutics by 450.7% in the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company’s stock worth $150,000 after purchasing an additional 83,172 shares during the period. Jane Street Group LLC lifted its position in Werewolf Therapeutics by 261.2% in the fourth quarter. Jane Street Group LLC now owns 54,713 shares of the company’s stock worth $81,000 after purchasing an additional 39,564 shares during the period. Finally, Vontobel Holding Ltd. acquired a new position in Werewolf Therapeutics during the first quarter worth $34,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on HOWL. Wedbush lowered their price objective on Werewolf Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research report on Friday, May 9th. Bank of America decreased their target price on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, August 25th. JMP Securities decreased their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. Finally, Citigroup restated a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $8.00.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $1.35 on Friday. The company has a quick ratio of 5.30, a current ratio of 5.30 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $61.74 million, a price-to-earnings ratio of -0.82 and a beta of 0.64. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $4.18. The stock’s 50-day simple moving average is $1.25 and its 200-day simple moving average is $1.14.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. As a group, analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.